scispace - formally typeset
Search or ask a question
Institution

University of Córdoba (Spain)

EducationCordova, Spain
About: University of Córdoba (Spain) is a education organization based out in Cordova, Spain. It is known for research contribution in the topics: Population & Catalysis. The organization has 12006 authors who have published 22998 publications receiving 537842 citations. The organization is also known as: University of Córdoba (Spain) & Universidad de Córdoba.


Papers
More filters
Journal ArticleDOI
TL;DR: E2 regulation of the VMH AMPK-SNS-BAT axis is an important determinant of energy balance and dysregulation in this axis may account for the common changes in energy homeostasis and obesity linked to dysfunction of the female gonadal axis.

334 citations

Journal ArticleDOI
TL;DR: This paper showed that grid-based and point-based simulations and statistical regressions, without deliberate adaptation or CO 2 fertilization effects, produce similar estimates of temperature impact on wheat yields at global and national scales.
Abstract: The potential impact of global temperature change on global crop yield has recently been assessed with different methods. Here we show that grid-based and point-based simulations and statistical regressions (from historic records), without deliberate adaptation or CO 2 fertilization effects, produce similar estimates of temperature impact on wheat yields at global and national scales. With a 1 °C global temperature increase, global wheat yield is projected to decline between 4.1% and 6.4%. Projected relative temperature impacts from different methods were similar for major wheat-producing countries China, India, USA and France, but less so for Russia. Point-based and grid-based simulations, and to some extent the statistical regressions, were consistent in projecting that warmer regions are likely to suffer more yield loss with increasing temperature than cooler regions. By forming a multi-method ensemble, it was possible to quantify 'method uncertainty' in addition to model uncertainty. This significantly improves confidence in estimates of climate impacts on global food security.

334 citations

Journal ArticleDOI
TL;DR: In this paper, a layered manganese oxide, Na0.6MnO2, stable at temperatures above 800 °C, was synthesized by using a sol-gel method that employs Mn(acac)3 (ac = acetylacetonate), Na2CO3 and propionic acid to form the resin framework.
Abstract: A layered sodium manganese oxide, Na0.6MnO2, stable at temperatures above 800 °C, was synthesized by using a sol–gel method that employs Mn(acac)3 (ac = acetylacetonate), Na2CO3 and propionic acid to form the resin framework. This layered bronze possesses a hexagonal, P2-type structure, in which the distortion associated with Mn3+ is hardly perceptible. It reacts slowly, though reversibly, with atmospheric moisture, which causes the interlayer spacing in the structure to increase by ca. 2.5 A, through intercalation of water molecules into the interlayer gap occupied by Na+ ions. The anhydrous material was tested as a cathode in sodium cells. Although the electrochemical intercalation of Na+ occurs in two steps, the host retains its main structural features, with a slight tendency in the interlayer spacing to contract as the sodium content increases. The similarity between the discharge and charge profiles of the first cycles reveals a quasi-reversible nature in the intercalation process and that the cell can deliver a constant specific capacity of ca. 140 A h kg−1 at 0.1 mA cm−2 when cycled in a voltage window of 3.8–2.0 V. However, the continuous strains and distortions resulting from the insertion and extraction of Na+ ions cause the host structure to gradually collapse and yield an amorphous material after the first eight cycles. This leads to a progressive reduction of the cell capacity, irrespective of the specific voltage window used.

333 citations

Journal ArticleDOI
TL;DR: Methods and strategies for efficient nuclear transformation of microalgae are outlined, the main difficulties associated with stable expression of transgenes are discussed, and new molecular biology tools are needed to standardize genetic modifications of micro algae.

333 citations

Journal ArticleDOI
TL;DR: The efficacy and safety of cefiderocol versus best available therapy in adults with serious carbapenem-resistant Gram-negative infections in 95 hospitals in 16 countries in North America, South America, Europe, and Asia is assessed.
Abstract: Summary Background New antibiotics are needed for the treatment of patients with life-threatening carbapenem-resistant Gram-negative infections. We assessed the efficacy and safety of cefiderocol versus best available therapy in adults with serious carbapenem-resistant Gram-negative infections. Methods We did a randomised, open-label, multicentre, parallel-group, pathogen-focused, descriptive, phase 3 study in 95 hospitals in 16 countries in North America, South America, Europe, and Asia. We enrolled patients aged 18 years or older admitted to hospital with nosocomial pneumonia, bloodstream infections or sepsis, or complicated urinary tract infections (UTI), and evidence of a carbapenem-resistant Gram-negative pathogen. Participants were randomly assigned (2:1 by interactive web or voice response system) to receive either a 3-h intravenous infusion of cefiderocol 2 g every 8 h or best available therapy (pre-specified by the investigator before randomisation and comprised of a maximum of three drugs) for 7–14 days. For patients with pneumonia or bloodstream infection or sepsis, cefiderocol treatment could be combined with one adjunctive antibiotic (excluding polymyxins, cephalosporins, and carbapenems). The primary endpoint for patients with nosocomial pneumonia or bloodstream infection or sepsis was clinical cure at test of cure (7 days [plus or minus 2] after the end of treatment) in the carbapenem-resistant microbiological intention-to-treat population (ITT; ie, patients with a confirmed carbapenem-resistant Gram-negative pathogen receiving at least one dose of study drug). For patients with complicated UTI, the primary endpoint was microbiological eradication at test of cure in the carbapenem-resistant microbiological ITT population. Safety was evaluated in the safety population, consisting of all patients who received at least one dose of study drug. Mortality was reported through to the end of study visit (28 days [plus or minus 3] after the end of treatment). Summary statistics, including within-arm 95% CIs calculated using the Clopper-Pearson method, were collected for the primary and safety endpoints. This trial is registered with ClinicalTrials.gov ( NCT02714595 ) and EudraCT (2015-004703-23). Findings Between Sept 7, 2016, and April 22, 2019, we randomly assigned 152 patients to treatment, 101 to cefiderocol, 51 to best available therapy. 150 patients received treatment: 101 cefiderocol (85 [85%] received monotherapy) and 49 best available therapy (30 [61%] received combination therapy). In 118 patients in the carbapenem-resistant microbiological ITT population, the most frequent carbapenem-resistant pathogens were Acinetobacter baumannii (in 54 patients [46%]), Klebsiella pneumoniae (in 39 patients [33%]), and Pseudomonas aeruginosa (in 22 patients [19%]). In the same population, for patients with nosocomial pneumonia, clinical cure was achieved by 20 (50%, 95% CI 33·8–66·2) of 40 patients in the cefiderocol group and ten (53%, 28·9–75·6) of 19 patients in the best available therapy group; for patients with bloodstream infection or sepsis, clinical cure was achieved by ten (43%, 23·2–65·5) of 23 patients in the cefiderocol group and six (43%, 17·7–71·1) of 14 patients in the best available therapy group. For patients with complicated UTIs, microbiological eradication was achieved by nine (53%, 27·8–77·0) of 17 patients in the cefiderocol group and one (20%, 0·5–71·6) of five patients in the best available therapy group. In the safety population, treatment-emergent adverse events were noted for 91% (92 patients of 101) of the cefiderocol group and 96% (47 patients of 49) of the best available therapy group. 34 (34%) of 101 patients receiving cefiderocol and nine (18%) of 49 patients receiving best available therapy died by the end of the study; one of these deaths (in the best available therapy group) was considered to be related to the study drug. Interpretation Cefiderocol had similar clinical and microbiological efficacy to best available therapy in this heterogeneous patient population with infections caused by carbapenem-resistant Gram-negative bacteria. Numerically more deaths occurred in the cefiderocol group, primarily in the patient subset with Acinetobacter spp infections. Collectively, the findings from this study support cefiderocol as an option for the treatment of carbapenem-resistant infections in patients with limited treatment options. Funding Shionogi.

333 citations


Authors

Showing all 12089 results

NameH-indexPapersCitations
Jose M. Ordovas123102470978
Liang Cheng116177965520
Pedro W. Crous11580951925
Munther A. Khamashta10962350205
Luis Serrano10545242515
Raymond Vanholder10384140861
Carlos Dieguez10154536404
David G. Bostwick9940331638
Leon V. Kochian9526631301
Abhay Ashtekar9436637508
Néstor Armesto9336926848
Manuel Hidalgo9253841330
Rafael de Cabo9131735020
Harald Mischak9044527472
Manuel Tena-Sempere8735123100
Network Information
Related Institutions (5)
Complutense University of Madrid
90.2K papers, 2.1M citations

92% related

Autonomous University of Barcelona
80.5K papers, 2.3M citations

92% related

University of Valencia
65.6K papers, 1.7M citations

91% related

Ghent University
111K papers, 3.7M citations

90% related

University of Barcelona
108.5K papers, 3.7M citations

90% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202333
2022133
20211,640
20201,619
20191,517
20181,348